Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

• The most recent release (April 14, 2026) announces a presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 21, 2026.
• Content includes a corporate update and MDNA113 preclinical data from the AACR Annual Meeting.
• This follows the March 18, 2026 announcement regarding the same AACR presentation of updated pre-clinical data for MDNA113.
• The February 13, 2026 quarterly results showed cash of $10.6 million with a runway into Q3 2026 and clinical updates on MDNA11 (ORR 36-43%) and Bizaxofusp (OS doubling in GBM).
• Historical data from November 2025 indicated a higher cash balance ($15.7 million) and the initiation of the NEO-CYT trial collaboration with Fondazione Melanoma Onlus.

• The April 14 announcement is confirmatory rather than transformative, reiterating an already disclosed presentation schedule (AACR data).
• No new clinical efficacy data or financial milestones are introduced in this specific release; it serves as standard investor relations visibility.
• Given the stock's significant decline from $1.64 to $0.65 despite positive clinical news in February and March, the market appears to be pricing in capital dilution risks rather than clinical success alone.
• The materiality is neutral because the information was largely anticipated by the previous month's release cycle and does not alter the fundamental cash runway timeline or clinical trajectory.

• Company: Medicenna Therapeutics is a clinical-stage biopharmaceutical company focused on oncology immunotherapies.
• Flagship Project: MDNA11, a long-acting IL-2 Superkine designed to activate CD8+ T cells while sparing regulatory T cells.
• Pipeline Assets:
  • MDNA113: First-in-class tumor-anchored anti-PD-1 x IL-2 bifunctional superkine (Preclinical/IND stage).
  • Bizaxofusp (MDNA55): IL-4 Empowered Superkine for recurrent glioblastoma (Phase 2b completed, seeking partnership).
• Development Status: MDNA11 is in Phase 1/2 ABILITY-1 trial; Bizaxofusp has shown median OS of 13.6 months vs 7 months standard care in Phase 2b.